Sana Biotechnology, Inc. (SANA)
| Market Cap | 4.34B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -285.31M |
| Shares Out | 183.81M |
| EPS (ttm) | -1.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $23.59 |
| Previous Close | $25.20 |
| Change ($) | -1.61 |
| Change (%) | -6.39% |
| Day's Open | 24.94 |
| Day's Range | 23.04 - 25.48 |
| Day's Volume | 138,243 |
| 52-Week Range | 21.21 - 44.60 |
– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogen results in tumor eradication – – Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in tu...
Expects to present data at multiple scientific conferences in 2021
Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
MADISON, Wis. and SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, a...
CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...
SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized...
Sana Biotechnology raised $587.
SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its ...
Sana Biotechnology — the Seattle upstart that's looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall…
The Seattle, Wash.-based biotech company says it will raise the funds by offering 15 million shares at $20 to $23 per share.
Sana Biotechnology is following the Moderna playbook to a tee: Promise a lot based on very early science, be vague, nab a major VC raise, then gun for an IPO.
The Seattle-based gene therapy startup filed with the U.S. Securities and Exchange Commission on Wednesday.
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the companyu2019s cell-based therapy discovery and...
Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest...
Sana Biotechnology, a preclinical biotech developing engineered cell therapies for multiple indications, filed on Wednesday with the SEC to raise up to $150 million in an initial public offering.
Sana Biotechnology, Inc. has filed to go public with an IPO on the NASDAQ.
UC San Francisco scientists have discovered a new way to control the immune system's "natural killer" (NK) cells, a finding with implications for novel cell therapies and tissue implants t...
About SANA
Sana Biotechnology was founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologics to clinical practice. Our long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access t... [Read more...]
| Industry Biotechnology | IPO Date Feb 4, 2021 |
| CEO Steven D. Harr, M.D. | Employees 263 |
| Stock Exchange NASDAQ | Ticker Symbol SANA |
Analyst Forecasts
The average 12-month stock price forecast for SANA is 41.33, which is an increase of 75.20% from the latest price.